Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
- Conditions
- Interventions
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05096715
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2022-10-17
- Target Recruit Count
- 2
- Registration Number
- NCT05093608
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 690
- Registration Number
- NCT05091567
- Locations
- 🇺🇸
Florida Cancer Specialists - Fort Myers (Broadway), Fort Myers, Florida, United States
🇺🇸Florida Cancer Specialist, North Region, Saint Petersburg, Florida, United States
🇺🇸SCRI Florida Cancer Specialists PAN, Tallahassee, Florida, United States
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
- Conditions
- Advanced Breast CarcinomaAdvanced Endometrial CarcinomaAdvanced Fallopian Tube CarcinomaAdvanced Hepatocellular CarcinomaAdvanced Malignant Abdominal NeoplasmAdvanced Malignant Female Reproductive System NeoplasmAdvanced Malignant Thoracic NeoplasmAdvanced Ovarian CarcinomaAdvanced Primary Peritoneal CarcinomaAdvanced Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT05092373
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
- Conditions
- Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaStage IV Sinonasal Cancer AJCC v8Metastatic Hypopharyngeal Squamous Cell CarcinomaMetastatic Nasopharyngeal Squamous Cell CarcinomaClinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Metastatic Lip and Oral Cavity CarcinomaMetastatic Nasal Cavity Squamous Cell CarcinomaStage IV Hypopharyngeal Carcinoma AJCC v8Stage IV Laryngeal Cancer AJCC v8
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 430
- Registration Number
- NCT05063552
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Epic Care-Dublin, Dublin, California, United States
🇺🇸Epic Care Partners in Cancer Care, Emeryville, California, United States
Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection
- Conditions
- Interventions
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 7
- Registration Number
- NCT05060003
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
- Conditions
- Interventions
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 189
- Registration Number
- NCT05058651
- Locations
- 🇺🇸
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
🇺🇸Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸Kaiser Permanente-Anaheim, Anaheim, California, United States
Radiotherapy in Combination with Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC
- Conditions
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 11
- Registration Number
- NCT05053737
- Locations
- 🇺🇸
Colorado Research Center, Aurora, Colorado, United States
🇺🇸Memorial Hospital North, Colorado Springs, Colorado, United States
🇺🇸Memorial Health Central, Colorado Springs, Colorado, United States
A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT05047250
- Locations
- 🇨🇳
The First Affiliated Hospital Of Jinzhou Medical University, Jinzhou City, China
🇨🇳Linyishi Cancer Hospital, Linyi City, China
🇨🇳Jiangsu Cancer Hospital, Nanjing City, China
Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).
- Conditions
- Interventions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2022-10-03
- Target Recruit Count
- 36
- Registration Number
- NCT05038657
- Locations
- 🇬🇧
University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.